CN103079566B - 作为组胺h3受体配体的杂环基化合物 - Google Patents
作为组胺h3受体配体的杂环基化合物 Download PDFInfo
- Publication number
- CN103079566B CN103079566B CN201080068911.8A CN201080068911A CN103079566B CN 103079566 B CN103079566 B CN 103079566B CN 201080068911 A CN201080068911 A CN 201080068911A CN 103079566 B CN103079566 B CN 103079566B
- Authority
- CN
- China
- Prior art keywords
- compound
- piperidin
- formula
- thiazolo
- yloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract description 8
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract description 3
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract description 3
- 239000003446 ligand Substances 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 152
- 238000002360 preparation method Methods 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 8
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 5
- 208000008589 Obesity Diseases 0.000 claims abstract description 4
- 208000002193 Pain Diseases 0.000 claims abstract description 4
- 235000020824 obesity Nutrition 0.000 claims abstract description 4
- 208000019116 sleep disease Diseases 0.000 claims abstract description 4
- -1 4-cyclobutyl-cyclohexyloxy Chemical group 0.000 claims description 31
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 28
- 229960001340 histamine Drugs 0.000 claims description 14
- 238000005859 coupling reaction Methods 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 12
- 238000010168 coupling process Methods 0.000 claims description 12
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229940095064 tartrate Drugs 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- ZTLBCQRDLSQPCC-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.S1C=2CN(C(=O)CC)CCC=2N=C1OC(CC1)CCN1C1CCC1 ZTLBCQRDLSQPCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- FLNUILBNSMSXDI-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-2-cyclopropylethanone Chemical compound C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)CC1CC1 FLNUILBNSMSXDI-UHFFFAOYSA-N 0.000 claims description 2
- QSKIGGHXASLHQY-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-2-methylpropan-1-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.S1C=2CN(C(=O)C(C)C)CCC=2N=C1OC(CC1)CCN1C1CCC1 QSKIGGHXASLHQY-UHFFFAOYSA-N 0.000 claims description 2
- XDFBBOFWFDOQOW-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-2-morpholin-4-ylethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)CN1CCOCC1 XDFBBOFWFDOQOW-UHFFFAOYSA-N 0.000 claims description 2
- KXTHPSOIZPDDLC-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-2-piperidin-1-ylethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)CN1CCCCC1 KXTHPSOIZPDDLC-UHFFFAOYSA-N 0.000 claims description 2
- RKZQGVFHVGBKPJ-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-3-methylbutan-1-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.S1C=2CN(C(=O)CC(C)C)CCC=2N=C1OC(CC1)CCN1C1CCC1 RKZQGVFHVGBKPJ-UHFFFAOYSA-N 0.000 claims description 2
- JZFVBOXJQDYGAC-UHFFFAOYSA-N 2-(1-cyclobutylpiperidin-4-yl)oxy-5-(2-fluorophenyl)sulfonyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine 2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.FC1=CC=CC=C1S(=O)(=O)N1CC(SC(OC2CCN(CC2)C2CCC2)=N2)=C2CC1 JZFVBOXJQDYGAC-UHFFFAOYSA-N 0.000 claims description 2
- OICHKSDKQUHAAW-UHFFFAOYSA-N 2-(1-cyclobutylpiperidin-4-yl)oxy-5-[6-(trifluoromethyl)pyridin-3-yl]-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine Chemical compound C1=NC(C(F)(F)F)=CC=C1N1CC(SC(OC2CCN(CC2)C2CCC2)=N2)=C2CC1 OICHKSDKQUHAAW-UHFFFAOYSA-N 0.000 claims description 2
- GECQXBVQNJEQHM-UHFFFAOYSA-N 2-(1-cyclobutylpiperidin-4-yl)oxy-5-methylsulfonyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine Chemical compound S1C=2CN(S(=O)(=O)C)CCC=2N=C1OC(CC1)CCN1C1CCC1 GECQXBVQNJEQHM-UHFFFAOYSA-N 0.000 claims description 2
- QDQDQGKOWGETQC-UHFFFAOYSA-N 2-(1-cyclobutylpiperidin-4-yl)oxy-5-pyridin-3-yl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CCC1N1CCC(OC=2SC=3CN(CCC=3N=2)C=2C=NC=CC=2)CC1 QDQDQGKOWGETQC-UHFFFAOYSA-N 0.000 claims description 2
- UCZCAAKMXYSTHZ-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-3-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-cyclopropylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CN(CCC3)C3CCC3)SC=2CN1C(=O)C1CC1 UCZCAAKMXYSTHZ-UHFFFAOYSA-N 0.000 claims description 2
- BTBZVVSBDLMTRH-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-(2-fluorophenyl)methanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.FC1=CC=CC=C1C(=O)N1CC(SC(OC2CCN(CC2)C2CCC2)=N2)=C2CC1 BTBZVVSBDLMTRH-UHFFFAOYSA-N 0.000 claims description 2
- UGEVDFZCBQVAPL-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-(4-methoxyphenyl)methanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1=CC(OC)=CC=C1C(=O)N1CC(SC(OC2CCN(CC2)C2CCC2)=N2)=C2CC1 UGEVDFZCBQVAPL-UHFFFAOYSA-N 0.000 claims description 2
- SPTPPVFWPBQUCH-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-(oxan-4-yl)methanone Chemical compound C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)C1CCOCC1 SPTPPVFWPBQUCH-UHFFFAOYSA-N 0.000 claims description 2
- BNJHMUOQBORPSS-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-[6-(trifluoromethyl)pyridin-3-yl]methanone Chemical compound C1=NC(C(F)(F)F)=CC=C1C(=O)N1CC(SC(OC2CCN(CC2)C2CCC2)=N2)=C2CC1 BNJHMUOQBORPSS-UHFFFAOYSA-N 0.000 claims description 2
- CIJSRQAAAUBOGY-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-cyclopentylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)C1CCCC1 CIJSRQAAAUBOGY-UHFFFAOYSA-N 0.000 claims description 2
- WRJNPYAXURHACS-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-cyclopropylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)C1CC1 WRJNPYAXURHACS-UHFFFAOYSA-N 0.000 claims description 2
- YJSMZVNZWQFKDL-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-morpholin-4-ylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)N1CCOCC1 YJSMZVNZWQFKDL-UHFFFAOYSA-N 0.000 claims description 2
- ICVRDYPBYNWZHS-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-piperidin-1-ylmethanone;hydrochloride Chemical compound Cl.C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)N1CCCCC1 ICVRDYPBYNWZHS-UHFFFAOYSA-N 0.000 claims description 2
- KPDMUXFBYXSFBS-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-pyridin-3-ylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C=1C=CN=CC=1C(=O)N(CC=1S2)CCC=1N=C2OC(CC1)CCN1C1CCC1 KPDMUXFBYXSFBS-UHFFFAOYSA-N 0.000 claims description 2
- QIXZAALZAOKPOR-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]-pyridin-4-ylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C=1C=NC=CC=1C(=O)N(CC=1S2)CCC=1N=C2OC(CC1)CCN1C1CCC1 QIXZAALZAOKPOR-UHFFFAOYSA-N 0.000 claims description 2
- CYPUNNQDNKXBOT-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-5h-[1,3]thiazolo[5,4-b]pyridin-4-yl]-cyclopropylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CCC=2N=C(OC3CCN(CC3)C3CCC3)SC=2N1C(=O)C1CC1 CYPUNNQDNKXBOT-UHFFFAOYSA-N 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- SXYNDJCTOVAETQ-UHFFFAOYSA-N cyclobutyl-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]methanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CCN(CC3)C3CCC3)SC=2CN1C(=O)C1CCC1 SXYNDJCTOVAETQ-UHFFFAOYSA-N 0.000 claims description 2
- TUZWXTQJSBGMQF-UHFFFAOYSA-N cyclobutyl-[2-(1-cyclopropylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]methanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CCN(CC3)C3CC3)SC=2CN1C(=O)C1CCC1 TUZWXTQJSBGMQF-UHFFFAOYSA-N 0.000 claims description 2
- YVQJZSGSTWBWOC-UHFFFAOYSA-N cyclobutyl-[2-(1-propan-2-ylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]methanone Chemical compound C1CN(C(C)C)CCC1OC(S1)=NC2=C1CN(C(=O)C1CCC1)CC2 YVQJZSGSTWBWOC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- MZDRZXSDEAHJEU-UHFFFAOYSA-N cyclopropyl-[2-(1-cyclopropylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]methanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC=2N=C(OC3CCN(CC3)C3CC3)SC=2CN1C(=O)C1CC1 MZDRZXSDEAHJEU-UHFFFAOYSA-N 0.000 claims description 2
- DYXVYNGGEKWDLN-UHFFFAOYSA-N cyclopropyl-[2-(1-propan-2-ylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]methanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CN(C(C)C)CCC1OC(S1)=NC2=C1CN(C(=O)C1CC1)CC2 DYXVYNGGEKWDLN-UHFFFAOYSA-N 0.000 claims description 2
- IZZXICOIWKYZLI-UHFFFAOYSA-N cyclopropyl-[2-[1-(2-methylpropyl)piperidin-4-yl]oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]methanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CN(CC(C)C)CCC1OC(S1)=NC2=C1CN(C(=O)C1CC1)CC2 IZZXICOIWKYZLI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 21
- 208000035475 disorder Diseases 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 description 76
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 239000003039 volatile agent Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 229940127285 new chemical entity Drugs 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 235000012631 food intake Nutrition 0.000 description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- XNQIOISZPFVUFG-RXMQYKEDSA-N (R)-alpha-methylhistamine Chemical compound C[C@@H](N)CC1=CN=CN1 XNQIOISZPFVUFG-RXMQYKEDSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 4
- 239000012414 tert-butyl nitrite Substances 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- DFNHWMSTHVIRFR-UHFFFAOYSA-N 1-cyclobutylpiperidin-4-ol Chemical compound C1CC(O)CCN1C1CCC1 DFNHWMSTHVIRFR-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- RGWGRRBHQUREDE-UHFFFAOYSA-N tert-butyl 3-bromo-4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C(Br)C1 RGWGRRBHQUREDE-UHFFFAOYSA-N 0.000 description 3
- IYHSCTMUOVWIJY-UHFFFAOYSA-N tert-butyl n-(2-bromo-4,5,6,7-tetrahydro-1,3-benzothiazol-6-yl)carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CCC2=C1SC(Br)=N2 IYHSCTMUOVWIJY-UHFFFAOYSA-N 0.000 description 3
- MSSYLWFGPLNSQI-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CCC=2N=C1OC(CC1)CCN1C1CCC1 MSSYLWFGPLNSQI-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- ZEKZZGYAMXXHTQ-UHFFFAOYSA-N 2-(1-cyclobutylpiperidin-4-yl)oxy-4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridine Chemical compound C1CCC1N1CCC(OC=2SC=3CNCCC=3N=2)CC1 ZEKZZGYAMXXHTQ-UHFFFAOYSA-N 0.000 description 2
- BKZWJPJKNKMPQJ-UHFFFAOYSA-N 2-bromo-4,5,6,7-tetrahydro-1,3-benzothiazol-6-amine Chemical compound C1C(N)CCC2=C1SC(Br)=N2 BKZWJPJKNKMPQJ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 0 CC(*)*1*C(N=C(*2)OC3*CC(C)(*)N(*)*C3)=C2*(C2)*2*(*)C1 Chemical compound CC(*)*1*C(N=C(*2)OC3*CC(C)(*)N(*)*C3)=C2*(C2)*2*(*)C1 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000001358 L(+)-tartaric acid Substances 0.000 description 2
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920005439 Perspex® Polymers 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000037411 cognitive enhancing Effects 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- PKCWKNXUGZAUMT-UHFFFAOYSA-N n-[2-(1-cyclobutylpiperidin-4-yl)oxy-4,5,6,7-tetrahydro-1,3-benzothiazol-6-yl]propanamide Chemical compound S1C=2CC(NC(=O)CC)CCC=2N=C1OC(CC1)CCN1C1CCC1 PKCWKNXUGZAUMT-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- 239000013062 quality control Sample Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RWZQGFARQCIROR-UHFFFAOYSA-N tert-butyl 2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate Chemical compound S1C=2CN(C(=O)OC(C)(C)C)CCC=2N=C1OC(CC1)CCN1C1CCC1 RWZQGFARQCIROR-UHFFFAOYSA-N 0.000 description 2
- BMLHPGOMLGKYIJ-UHFFFAOYSA-N tert-butyl 2-amino-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1SC(N)=N2 BMLHPGOMLGKYIJ-UHFFFAOYSA-N 0.000 description 2
- RXXKNZKFRAFFOH-UHFFFAOYSA-N tert-butyl 2-bromo-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1SC(Br)=N2 RXXKNZKFRAFFOH-UHFFFAOYSA-N 0.000 description 2
- KBJFODXPSAJIBX-UHFFFAOYSA-N 1-(cyclopropanecarbonyl)azepan-4-one Chemical compound C1CCC(=O)CCN1C(=O)C1CC1 KBJFODXPSAJIBX-UHFFFAOYSA-N 0.000 description 1
- QVLKOXLLRLMXDL-UHFFFAOYSA-N 1-[2-(1-cyclobutyl-3-fluoropiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CCC=2N=C1OC(C(C1)F)CCN1C1CCC1 QVLKOXLLRLMXDL-UHFFFAOYSA-N 0.000 description 1
- NWYIFWNGUWGKBB-UHFFFAOYSA-N 1-[2-(1-cyclobutyl-3-methylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CCC=2N=C1OC(C(C1)C)CCN1C1CCC1 NWYIFWNGUWGKBB-UHFFFAOYSA-N 0.000 description 1
- YUNNYLNXZGMROC-UHFFFAOYSA-N 1-[2-(1-cyclobutylazepan-4-yl)oxy-4,6-dihydropyrrolo[3,4-d][1,3]thiazol-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CC=2N=C1OC(CC1)CCCN1C1CCC1 YUNNYLNXZGMROC-UHFFFAOYSA-N 0.000 description 1
- RHBXIASJOCVUGY-UHFFFAOYSA-N 1-[2-(1-cyclobutylazepan-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CCC=2N=C1OC(CC1)CCCN1C1CCC1 RHBXIASJOCVUGY-UHFFFAOYSA-N 0.000 description 1
- LBPRARPMASUKEI-UHFFFAOYSA-N 1-[2-(1-cyclobutylazetidin-3-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CCC=2N=C1OC(C1)CN1C1CCC1 LBPRARPMASUKEI-UHFFFAOYSA-N 0.000 description 1
- FOSHPMOCJYMEPU-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-4,6-dihydropyrrolo[3,4-d][1,3]thiazol-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CC=2N=C1OC(CC1)CCN1C1CCC1 FOSHPMOCJYMEPU-UHFFFAOYSA-N 0.000 description 1
- JUJQISAMAVYLEH-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-4-methyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2C(C)N(C(=O)CC)CCC=2N=C1OC(CC1)CCN1C1CCC1 JUJQISAMAVYLEH-UHFFFAOYSA-N 0.000 description 1
- WQNZHBVKEXLBOK-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-5,6-dihydropyrrolo[3,2-d][1,3]thiazol-4-yl]propan-1-one Chemical compound S1C=2N(C(=O)CC)CCC=2N=C1OC(CC1)CCN1C1CCC1 WQNZHBVKEXLBOK-UHFFFAOYSA-N 0.000 description 1
- QUXDYNHLQIJBNN-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-5h-[1,3]thiazolo[5,4-b]pyridin-4-yl]propan-1-one Chemical compound S1C=2N(C(=O)CC)CCCC=2N=C1OC(CC1)CCN1C1CCC1 QUXDYNHLQIJBNN-UHFFFAOYSA-N 0.000 description 1
- IGIGYRUJDJOYIC-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-6-methyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound N=1C=2CC(C)N(C(=O)CC)CC=2SC=1OC(CC1)CCN1C1CCC1 IGIGYRUJDJOYIC-UHFFFAOYSA-N 0.000 description 1
- WEZXOUOPMBOVDX-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-7-fluoro-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CC(F)C=2N=C1OC(CC1)CCN1C1CCC1 WEZXOUOPMBOVDX-UHFFFAOYSA-N 0.000 description 1
- PCNFJOWKUUPGKK-UHFFFAOYSA-N 1-[2-(1-cyclobutylpiperidin-4-yl)oxy-7-methyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CC(C)C=2N=C1OC(CC1)CCN1C1CCC1 PCNFJOWKUUPGKK-UHFFFAOYSA-N 0.000 description 1
- MPNDUGLSHMLMNP-UHFFFAOYSA-N 1-[2-(1-cyclobutylpyrrolidin-3-yl)oxy-4,6-dihydropyrrolo[3,4-d][1,3]thiazol-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CC=2N=C1OC(C1)CCN1C1CCC1 MPNDUGLSHMLMNP-UHFFFAOYSA-N 0.000 description 1
- OJTWDLYGKPIEGH-UHFFFAOYSA-N 1-[2-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CCC=2N=C1OC1CCN(CC(F)(F)F)CC1 OJTWDLYGKPIEGH-UHFFFAOYSA-N 0.000 description 1
- VFZHZNKPZWKPGT-UHFFFAOYSA-N 1-[2-[1-(2-hydroxyethyl)piperidin-4-yl]oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound S1C=2CN(C(=O)CC)CCC=2N=C1OC1CCN(CCO)CC1 VFZHZNKPZWKPGT-UHFFFAOYSA-N 0.000 description 1
- HKFAWRDDACXPLV-UHFFFAOYSA-N 1-[2-[1-(ethoxymethyl)piperidin-4-yl]oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-1-one Chemical compound C1CN(COCC)CCC1OC(S1)=NC2=C1CN(C(=O)CC)CC2 HKFAWRDDACXPLV-UHFFFAOYSA-N 0.000 description 1
- TZJYXZROVNJDGC-UHFFFAOYSA-N 1-cyclobutyl-4-[(5-propanoyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-2-yl)oxy]piperidine-3-carbonitrile Chemical compound S1C=2CN(C(=O)CC)CCC=2N=C1OC(C(C1)C#N)CCN1C1CCC1 TZJYXZROVNJDGC-UHFFFAOYSA-N 0.000 description 1
- WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XAUATCQEBHTSHP-UHFFFAOYSA-N 5-bromo-1-(cyclopropanecarbonyl)azepan-4-one Chemical compound C1CC(=O)C(Br)CCN1C(=O)C1CC1 XAUATCQEBHTSHP-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- PHYOKROHFSOQGV-UHFFFAOYSA-N 6-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)N)=CC=C1N1CC(SC(OC2CCN(CC2)C2CCC2)=N2)=C2CC1 PHYOKROHFSOQGV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- LKENTYLPIUIMFG-UHFFFAOYSA-N CC(C1CCCC1)=O Chemical compound CC(C1CCCC1)=O LKENTYLPIUIMFG-UHFFFAOYSA-N 0.000 description 1
- VNMXIOWPBADSIC-UHFFFAOYSA-N CC(C1CCOCC1)=O Chemical compound CC(C1CCOCC1)=O VNMXIOWPBADSIC-UHFFFAOYSA-N 0.000 description 1
- WAPBWMNFSOOTGB-UHFFFAOYSA-N CC(CN1CCCCC1)=O Chemical compound CC(CN1CCCCC1)=O WAPBWMNFSOOTGB-UHFFFAOYSA-N 0.000 description 1
- LOBSVGRXQAHJDT-UHFFFAOYSA-N CC(CN1CCOCC1)=O Chemical compound CC(CN1CCOCC1)=O LOBSVGRXQAHJDT-UHFFFAOYSA-N 0.000 description 1
- KYWXRBNOYGGPIZ-UHFFFAOYSA-N CC(N1CCOCC1)=O Chemical compound CC(N1CCOCC1)=O KYWXRBNOYGGPIZ-UHFFFAOYSA-N 0.000 description 1
- QMATYTFXDIWACW-UHFFFAOYSA-N CC(c(cccc1)c1F)=O Chemical compound CC(c(cccc1)c1F)=O QMATYTFXDIWACW-UHFFFAOYSA-N 0.000 description 1
- WMQUKDQWMMOHSA-UHFFFAOYSA-N CC(c1ccncc1)=O Chemical compound CC(c1ccncc1)=O WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 1
- NAUKVLRFGMDIAN-UHFFFAOYSA-N CC(c1cnc(C(F)(F)F)cc1)=O Chemical compound CC(c1cnc(C(F)(F)F)cc1)=O NAUKVLRFGMDIAN-UHFFFAOYSA-N 0.000 description 1
- DRQGZMZPKOYPKW-UHFFFAOYSA-N CS(c(cccc1)c1F)(=O)=O Chemical compound CS(c(cccc1)c1F)(=O)=O DRQGZMZPKOYPKW-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 230000006179 O-acylation Effects 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- NJQQRQZJRDNEQQ-UHFFFAOYSA-N [2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-5h-[1,3]thiazolo[5,4-b]pyridin-4-yl]-cyclopropylmethanone Chemical compound C1CCC=2N=C(OC3CCN(CC3)C3CCC3)SC=2N1C(=O)C1CC1 NJQQRQZJRDNEQQ-UHFFFAOYSA-N 0.000 description 1
- PRWKPTHCGRFBLP-UHFFFAOYSA-N [3-[(5-cyclobutyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-2-yl)oxy]piperidin-1-yl]-cyclopropylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CCC(OC=2SC=3CN(CCC=3N=2)C2CCC2)CN1C(=O)C1CC1 PRWKPTHCGRFBLP-UHFFFAOYSA-N 0.000 description 1
- DULXQCHUPLLFLP-UHFFFAOYSA-N [4-[(5-cyclobutyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-2-yl)oxy]piperidin-1-yl]-cyclopropylmethanone;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CC(OC=2SC=3CN(CCC=3N=2)C2CCC2)CCN1C(=O)C1CC1 DULXQCHUPLLFLP-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- GMHPWGYTSXHHPI-UHFFFAOYSA-N azepan-4-one Chemical compound O=C1CCCNCC1 GMHPWGYTSXHHPI-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- NANPRQMTXLQPRB-UHFFFAOYSA-N cyclobutyl-[2-(1-cyclobutylpiperidin-4-yl)oxy-6,7-dihydro-5h-[1,3]thiazolo[5,4-b]pyridin-4-yl]methanone Chemical compound C1CCC=2N=C(OC3CCN(CC3)C3CCC3)SC=2N1C(=O)C1CCC1 NANPRQMTXLQPRB-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- JTLUDNNPYXJUBR-UHFFFAOYSA-N n-(2-bromo-4,5,6,7-tetrahydro-1,3-benzothiazol-6-yl)propanamide Chemical compound C1C(NC(=O)CC)CCC2=C1SC(Br)=N2 JTLUDNNPYXJUBR-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ORMQSOBDBIXCHD-UHFFFAOYSA-N tert-butyl n-(3-bromo-4-oxocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(=O)C(Br)C1 ORMQSOBDBIXCHD-UHFFFAOYSA-N 0.000 description 1
- WYVFPGFWUKBXPZ-UHFFFAOYSA-N tert-butyl n-(4-oxocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(=O)CC1 WYVFPGFWUKBXPZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及式(I)杂环基化合物和其可药用盐以及含有它们的组合物。本发明还涉及用于制备上述新化合物和其可药用盐的方法。所述式(I)化合物可用于治疗与组胺H3受体有关的多种疾病,例如认知障碍、睡眠障碍、肥胖和疼痛。
Description
技术领域
本发明涉及式(I)的杂环基化合物和它们的可药用盐、其制备方法以及含有它们的组合物,其用于治疗与组胺H3受体有关的多种疾病。
背景技术
组胺H3受体是G蛋白偶联受体(G-protein coupled receptor,GPCR)并且是组胺家族四种受体中的一种。组胺H3受体在1983年被鉴定出,其克隆和表征在1999年进行。组胺H3受体在中枢神经系统中以较大的程度表达而在周围神经系统以较小的程度表达。
文献证据表明,可将组胺H3受体用于治疗认知障碍(British Journal of Pharmacology,2008,154(6),1166-1181)、睡眠障碍(Trends in Pharmacology Science,2004,25(12),618-625)、肥胖症(Molecular Interventions,2006,6(2),77-88)和疼痛(Pain,2008,138(1),61-69)。
专利/专利申请US4695575、EP0151826、WO2010026113、WO2004022060和WO2003004480公开了作为组胺H3受体之配体的一系列化合物。虽然已经公开了一些组胺H3受体配体,但是在本研究领域的市场上至今没有推出化合物,因而仍存在发现新药的需要和眼界,该药具有新的化学结构用于治疗受组胺H3受体影响的疾病。
发明内容
本发明涉及新的式(I)的组胺H3受体配体或其可药用盐;
其中,
R1是-C(O)-R4、-S(O)2-R4、取代的或未取代的环烷基、芳基或杂芳基;其中取代基可以是一个或更多个并且独立选自氢、羟基、卤素、烷基、烷氧基、卤烷基或卤烷氧基;
R4是取代的或未取代的烷基、环烷基、环烷基烷基、芳基、杂芳基、杂环基或杂环基烷基;其中取代基可以是一个或更多个并且独立选自氢、羟基、卤素、烷基、烷氧基、卤烷基或卤烷氧基;
R5是氢、烷基或环烷基;
在每种情况下,R3独立选自氢、卤素、烷基或烷氧基;
R2是氢、取代的或未取代的烷基或环烷基;其中取代基可以是一个或更多个并且独立选自氢、羟基、卤素、烷基、烷氧基、卤烷基或卤烷氧基;
X是S、N或O;
Y是C或N;
“p”是0至2的整数;
“q”是0至2的整数;
“r”是0至1的整数。
本发明涉及治疗有效量的式(I)化合物在制备用于治疗与组胺H3受体有关的多种疾病的药物中的用途。
特别地,本发明的化合物可用于治疗多种疾病,例如认知障碍、睡眠障碍、肥胖症和疼痛。
在另一个方面中,本发明涉及含有治疗有效量的至少一种式(I)化合物及其可药用盐与可药用赋形剂混合的药物组合物。
在又一个方面中,本发明涉及用于使用式(I)化合物的方法。
在再一个方面中,本发明还涉及用于制备式(I)化合物及其可药用盐的方法。
本发明的代表性化合物包括以下详述的那些及其可药用盐。本发明不应解释为限于此:
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮酒石酸盐;
[2-(4-环丁基-环己氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-环丙基-甲酮酒石酸盐;
N-[2-(1-环丁基-哌啶-4-基氧基)-4,5,6,7-四氢-苯并噻唑-6-基]-丙酰胺;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-环丙基-甲酮酒石酸盐;
环丁基-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-(2-氟-苯基)-甲酮酒石酸盐;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-3-甲基-丁-1-酮酒石酸盐;
环丁基-[2-(1-异丙基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮;
环丙基-[2-(1-异丙基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
环丙基-[2-(1-环丙基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
环丁基-[2-(1-环丙基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-2-吗啉-4-基-乙酮酒石酸盐;
[4-(5-环丁基-6,7-二氢-4H-噻唑并[5,4-c]吡啶-2-基氧基)-哌啶-1-基]-环丙基-甲酮酒石酸盐;
[3-(5-环丁基-6,7-二氢-4H-噻唑并[5,4-c]吡啶-2-基氧基)-哌啶-1-基]-环丙基 -甲酮酒石酸盐;
[2-(1-环丁基-哌啶-3-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-环丙基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-吡啶-4-基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-(4-甲氧基-苯基)-甲酮酒石酸盐;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-2-哌啶-1-基-乙酮酒石酸盐;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-2-环丙基-乙酮;
2-(1-环丁基-哌啶-4-基氧基)-5-(2-氟-苯磺酰基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶酒石酸盐;
2-(1-环丁基-哌啶-4-基氧基)-5-甲磺酰基-6,7-二氢-4H-噻唑并[5,4-c]吡啶;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-2-甲基-丙-1-酮酒石酸盐;
2-(1-环丁基-哌啶-4-基氧基)-5-(2-三氟甲基-吡啶-5-基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶;
环丙基-[2-(1-异丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-(2-三氟甲基-吡啶-5-基)-甲酮;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-吡啶-3-基-甲酮酒石酸盐;
2-(1-环丁基-哌啶-4-基氧基)-5-吡啶-3-基-6,7-二氢-4H-噻唑并[5,4-c]吡啶酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-(四氢-吡喃-4-基)-甲酮;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-吗啉-4-基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-哌啶-1-基-甲酮盐酸盐;
6-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-烟酰胺;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-环戊基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-5H-噻唑并[5,4-b]吡啶-4-基]-环丙基-甲酮酒石酸盐;
环丙基-[2-(1-异丙基-哌啶-4-基氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-5H-噻唑并[5,4-b]吡啶-4-基]-环丙基-甲酮;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-5H-噻唑并[5,4-b]吡啶-4-基]-丙-1-酮;
环丁基-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-5H-噻唑并[5,4-b]吡啶-4-基]-甲酮;
N-[2-(1-环丁基-哌啶-4-基氧基)-4,5,6,7-四氢-苯并噻唑-7-基]-丙酰胺;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-唑并[5,4-c]吡啶-5-基]-丙-1-酮;
1-[2-(1-环丁基-哌啶-4-基氧基)-4,6-二氢-吡咯并[4,3-d]唑-5-基]-丙-1-酮;
N-[2-(1-环丁基-哌啶-4-基氧基)-5,6-二氢-4H-环戊并唑-5-基]-丙酰胺;
N-[2-(1-环丁基-哌啶-4-基氧基)-5,6-二氢-4H-环戊并噻唑-5-基]-丙酰胺;
1-[2-(1-环丁基-哌啶-4-基氧基)-4,6-二氢-吡咯并[4,3-d]噻唑-5-基]-丙-1-酮;
1-[2-(1-环丁基-哌啶-4-基氧基)-5,6-二氢-吡咯并[3,2-d]噻唑-4-基]-丙-1-酮;
N-[2-(1-环丁基-哌啶-4-基氧基)-5,6-二氢-4H-环戊并噻唑-6-基]-丙酰胺;
N-[2-(1-环丁基-哌啶-4-基氧基)-5,6-二氢-4H-环戊并唑-6-基]-丙酰胺;
1-[2-(1-环丁基-哌啶-4-基氧基)-5,6-二氢-吡咯并[3,2-d]唑-4-基]]-丙-1-酮;
1-[2-(1-环丁基-哌啶-4-基氧基)-4,6-二氢-吡咯并[4,3-d]唑-5-基]-丙-1-酮;
N-[2-(1-环丁基-哌啶-4-基氧基)-5,6-二氢-4H-环戊并唑-5-基]-丙酰胺;
1-[2-(1-环丁基-哌啶-4-基氧基)-4,6,7,8-四氢-噻唑并[5,4-c]氮杂-5-基]-丙-1-酮;
1-[2-(1-环丁基-哌啶-4-基氧基)-4-甲基-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮;
1-[2-(1-环丁基-哌啶-4-基氧基)-7-氟-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮;
1-[2-(1-环丁基-哌啶-4-基氧基)-7-甲基-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮;
1-[2-(1-环丁基-哌啶-4-基氧基)-6-甲基-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮;
1-[2-(1-环丁基-3-甲基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮;
1-[2-(1-环丁基-3-氟-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮;
1-环丁基-4-(5-丙酰基-4,5,6,7-四氢-噻唑并[5,4-c]吡啶-2-基氧基)-哌啶-3-甲腈;
1-[2-(1-环丁基-氮杂环庚-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮;
1-[2-(1-环丁基-氮杂环庚-4-基氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-丙-1-酮;
1-[2-(1-环丁基-吡咯烷-3-基氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-丙-1-酮;
1-[2-(1-环丁基-吡咯烷-3-基氧基)-4,6-二氢-吡咯并[4,3-d]噻唑-5-基]-丙-1-酮;
1-[2-(1-环丁基-氮杂环庚-4-基氧基)-4,6-二氢-吡咯并[4,3-d]噻唑-5-基]-丙-1-酮;
1-{2-[1-(2-羟基-乙基)-哌啶-4-基氧基]-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基}-丙-1-酮;
1-[2-(1-乙氧甲基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙 -1-酮;
1-{2-[1-(2,2,2-三氟-乙基)-哌啶-4-基氧基]-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基}-丙-1-酮;
1-[2-(1-环丁基-氮杂环丁-3-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮;及其可药用盐。
发明详述
除非另有所指,否则在本说明书和权利要求书中使用的以下术语具有以下给出的含义:
术语“卤素”意指氟、氯、溴或碘。
术语“烷基”意指直链或支链碳氢基团,其仅由碳和氢原子组成,不包括不饱和,具有1至8个碳原子并且通过单键连接至其余分子。示例性“烷基”包括甲基、乙基、正丙基、异丙基等。
术语“烷氧基”意指经由氧连接与分子其余部分相连接的烷基。示例性“烷氧基”包括甲氧基、乙氧基、丙氧基、异丙基氧基等。
术语“卤烷基”意指含有1至3个碳原子的直链或支链烷基基团。示例性“卤烷基”包括氟甲基、二氟甲基、三氟甲基、三氟乙基、氟乙基、二氟乙基等。
术语“卤烷氧基”意指含有1至3个碳原子的直链或支链烷氧基基团。示例性“卤烷氧基”包括氟甲氧基、二氟甲氧基、三氟甲氧基、三氟乙氧基、氟乙氧基、二氟乙氧基等。
术语“环烷基”意指3至8个碳原子的非芳香单环。示例性“环烷基”包括环丙基、环丁基、环戊基等。
术语“环烷基烷基”意指直接键合至烷基的环烷基环基团。
术语“芳基”意指来源于简单芳香环的任何官能团或取代基,示例性“芳基”包括苯基、萘基等。
术语“杂芳基”意指包含环结构的有机化合物,该环结构含有除碳之外的原子(例如硫、氧或氮)作为环的部分,这些额外的原子可在环中重复多于一次。这些环可以是简单芳香环。示例性“杂芳基”包括吡啶、嘧啶、苯并呋喃基、苯并噻吩、呋喃基、二氧戊环基(dioxalanyl)、吡咯基、 唑基、吡啶基、哒嗪基、嘧啶基、吡嗪基、喹啉基、吲哚基等。
术语“杂环基”意指2至7个碳原子的非芳香单环,其环结构包含1至3个杂原子,这些额外的原子可在环中重复多于一次。示例性“杂环基”包括吡咯烷基、哌啶基、哌嗪基、吗啉基等。
术语“杂环基烷基”意指直接键合至烷基的杂环基环基团。
术语“治疗”包括所有的含义,例如预防性的、保护性的和缓解性的。
短语“可药用盐”指所述物质或组合物必须在化学和/或毒物学上与其他成分(包括制剂)、所治疗的哺乳动物相容。
短语“治疗有效量”定义为本发明的化合物用于以下时的量:(i)治疗或预防特定疾病、病症或障碍,(ii)使特定疾病、病症或障碍的一种或更多种症状减弱、减轻或消除,(iii)预防或延缓本文中描述的特定疾病、病症或障碍的一种或更多种症状发作。
在不进一步纯化的情况下使用商业试剂。室温指25-40℃。除非另有所指,否则使用ESI条件进行所有的质谱。采用Bruker仪器在400MHz记录1H-NMR谱。将氘化氯仿(99.8%D)、甲醇或二甲亚砜用作溶剂。将TMS用作内参标准。化学位移值表示为百万分之一(δ)值。以下缩写用于NMR信号的多重性:s=单峰,bs=宽单峰,d=双峰,t=三重峰,q=四重峰,qui=五重峰,h=七重峰,dd=双二重峰,dt=双三重峰,tt=三重三重峰,m=多重峰。色谱法指使用100-200目硅胶进行的并且在氮气压力(快速色谱)条件下进行的柱色谱法。
由使用Chem Draw Ultra 7.0产生化合物命名。
药物组合物
为了在治疗中使用式(I)化合物,一般将它们根据标准制药实践配制成药物组合物。
可使用一种或更多种可药用赋形剂以常规方式配制本发明的药物组合物。可药用赋形剂是载体或稀释剂。因此,可配制本发明的活性化合物用于口服、鼻内或肠胃外(例如,静脉内、肌肉内或皮下)。此类药物组合物和制备其的方法为本领域所公知(参见,例如,Remington:The Science and Practice of Pharmacy(D.B.Troy编),第21版,Lippincott,Williams&Wilkins,2006年)。
活性化合物的剂量可有赖于一些因素(例如施用途径、患者的年龄和 重量、待治疗疾病的性质和严重性等类似因素)而改变。因此,本文中对药理有效量的通式(I)化合物的任何参考指的是上述因素。
制备方法
通过下述方案I制备式(I)化合物。
方案I
在上述方案I中,p是1;q是1;r是1;Y是N;X是S;R1是-C(O)-R4、-S(O)2-R4、取代的或未取代的环烷基、芳基或杂芳基,并且所有其他符号如上所述。
将式(1)化合物与式(2)化合物相偶联以形成式(3)化合物。使式(3)化合物脱保护以形成式(4)化合物。将式(4)化合物与式(5)化合物相偶联以形成式(I)化合物。
在上述制备的第一步骤中,将式(1)化合物与式(2)化合物相偶联以形成式(3)化合物。优选在溶剂(例如四氢呋喃、甲苯、乙酸乙酯、二氯甲烷、三乙胺、二甲基甲酰胺等或其混合物)中进行该反应并且优选通过使用四氢呋喃。所述反应可在碱(例如氢化钠、碳酸钠、碳酸钾、碳酸氢钠、氢氧化钠或其混合物)的存在下发生并且优选通过使用氢化钠。反应在室温下进行。反应可持续4至8小时,优选5至7小时。
在上述制备的第二步骤中,使式(3)化合物脱保护以形成式(4)化合物。优选在溶剂(例如四氢呋喃、甲苯、乙酸乙酯、二氯甲烷、乙腈、1,4-二乙双酮、二甲基甲酰胺等或其混合物)中进行该反应并且优选通过使用二氯甲烷。所述反应可在酸(例如三氟乙酸、硫酸、醋酸、高氯酸、盐酸等或其混合物)的存在下发生并且优选通过使用三氟乙酸。反应在60℃至85℃的温度下进行并且优选65℃至75℃的温度。反应可持续2至6小时,优选3至5小时。
在上述制备的第三步骤中,将式(4)化合物与式(5)化合物相偶联以形成式(I)化合物。优选在溶剂(例如二氯甲烷、四氢呋喃、甲苯、乙酸乙酯、二甲基甲酰胺等或其混合物)中进行该反应并且优选通过使用二氯甲烷。所述反应可在碱(例如三乙胺、碳酸钾、二异丙基乙胺和吡啶)的存在下发生并且优选通过使用三乙胺。反应在室温下进行。反应可持续15分钟至45分钟,优选25分钟至35分钟。
式(1)、式(2)和式(5)化合物可商购或者可使用已知过程通过常规方法或通过修饰进行制备。
还可通过使用下述方案II制备式(I)化合物。
方案II
在上述方案II中,p是1;q是2;r是1;Y是N;X是S;R1是-C(O)-R4、-S(O)2-R4、取代的或未取代的环烷基、芳基或杂芳基,并且所有其他符号如上述。
将式(6)化合物与式(5)化合物相偶联以形成式(7)化合物。使式(7)化合物溴化以形成式(8)化合物。使式(8)化合物环化以形成式(9)化合物。使式(9)化合物重氮化以形成式(10)化合物。将式(10)化合物与式(2)化合物相偶联以形成式(I)化合物。
在上述制备的第一步骤中,将式(6)化合物与式(5)化合物相偶联以形成式(7)化合物。优选在溶剂(例如四氢呋喃、甲苯、乙酸乙酯、二氯甲烷、二甲基甲酰胺等或其混合物)中进行该反应并且优选通过使用二氯甲烷。所述反应可在碱(例如三乙胺、碳酸钾、二异丙基乙胺和吡啶)的存在下发生并且优选通过使用三乙胺。反应在室温下进行。反应可持续15分钟至45分钟,优选25分钟至35分钟。
在上述制备的第二步骤中,使式(7)化合物溴化以形成式(8)化合物。所述反应可在酸(例如硫酸、醋酸、高氯酸、盐酸等或其混合物)的存在下发生并且优选通过使用醋酸。所述反应可在溴化剂(例如溴、溴化铜(II)、氢溴酸、N-溴代丁二酰亚胺、过溴化氢溴酸吡啶、四溴甲烷等或其混合物)的存在下发生并且优选通过使用溴。反应在室温下进行。反应可持续16小时至20小时,优选17小时至19小时。
在上述制备的第三步骤中,使式(8)化合物环化以形成式(9)化合物。该反应优选在溶剂(例如异丙醇、四氢呋喃、甲苯、乙酸乙酯、二氯甲烷、 三乙胺、二甲基甲酰胺等或其混合物)中进行并且优选通过使用异丙醇。所述反应可在尿素或硫脲的存在下发生。反应在60℃至85℃的温度下进行并且优选65℃至75℃的温度。反应可持续15分钟至45分钟,优选25分钟至35分钟。
在上述制备的第四步骤中,使式(9)化合物重氮化以形成式(10)化合物。该反应优选在溶剂(例如乙腈、四氢呋喃、异丙醇、甲苯、乙酸乙酯、二氯甲烷、三乙胺、二甲基甲酰胺等或其混合物)中进行并且优选通过使用乙腈。所述反应可在溴化剂(例如溴化铜(II)、氢溴酸、N-溴代丁二酰亚胺、过溴化氢溴酸吡啶、四溴甲烷等或其混合物)的存在下发生并且优选通过使用溴化铜(II)。所述反应可在亚硝酸烷基酯的存在下发生并且优选通过使用亚硝酸叔丁酯。反应在室温下进行。反应可持续15分钟至45分钟,优选25分钟至35分钟。
在上述制备的第五步骤中,将式(10)化合物与式(2)化合物相偶联以形成式(I)化合物。该反应优选在溶剂(例如四氢呋喃、甲苯、乙酸乙酯、二氯甲烷、三乙胺、二甲基甲酰胺等或其混合物)中进行并且优选通过使用四氢呋喃。所述反应可在碱(例如氢化钠、碳酸钠、碳酸钾、碳酸氢钠、氢氧化钠或其混合物)的存在下发生并且优选通过使用氢化钠。所述反应可在尿素或硫脲的存在下发生。反应在60℃至85℃的温度下进行并且优选65℃至75℃的温度。反应可持续12至18小时,优选14至16小时。
式(2)、式(5)和式(6)化合物可商购或者可使用已知过程通过常规方法或通过修饰进行制备。
还可通过使用下述方案III制备式(I)化合物
方案III
在上述方案III中,p是1;q是1;r是1;Y是C;X是S;R1是 并且所有其他符号如上述。
将式(11)化合物与式(5)化合物相偶联以形成式(12)化合物。将式(12)化合物与式(2)化合物相偶联以形成式(I)化合物。
在上述制备的第一步骤中,将式(11)化合物与式(5)化合物相偶联以形成式(12)化合物。该反应优选在溶剂(例如四氢呋喃、甲苯、乙酸乙酯、二氯甲烷、二甲基甲酰胺等或其混合物)中进行并且优选通过使用二氯甲烷。所述反应可在碱(例如三乙胺、碳酸钾、二异丙基乙胺和吡啶)的存在下发生并且优选通过使用三乙胺。反应在室温下进行。反应可持续15分钟至45分钟,优选25分钟至35分钟。
在上述制备的第二步骤中,将式(12)化合物与式(2)化合物相偶联以形成式(I)化合物。该反应优选在溶剂(例如四氢呋喃、甲苯、乙酸乙酯、二氯甲烷、三乙胺、二甲基甲酰胺等或其混合物)中进行并且优选通过使用二甲基甲酰胺。所述反应可在碱(例如氢化钠、碳酸钠、碳酸钾、碳酸氢钠、氢氧化钠或其混合物)的存在下发生并且优选通过使用氢化钠。反应在室温下进行。反应可持续45至51小时,优选47至49小时。
式(2)、式(5)和式(11)化合物可商购或者可使用已知过程通过常规方法或通过修饰进行制备。
如果有必要,可进行以下步骤中的任何一个或多于一个,
i)将式(I)化合物转化成另一式(I)化合物或者
ii)形成可药用盐。
可使用公知反应通过进一步化学修饰进行过程(i),这些反应是例如氧化、还原、保护、脱保护、重排反应、卤化、羟基化、烷基化、烷硫基化、脱甲基化、O-烷基化、O-酰化、N-烷基化、N-烯基化、N-酰化、N-氰化、N-磺酰化、使用过渡金属的偶联反应等。
在过程(ii)中,可通过与适当的酸或酸衍生物反应常规地制备可药用盐。
合适的可药用盐对本领域技术人员而言将是明显的并且包括在J.Pharm.Sci.,1977,66,1-19中描述的那些,例如与无机酸(例如盐酸、氢溴酸、硫酸、硝酸或磷酸)和有机酸(例如琥珀酸、马来酸、醋酸、富马酸、柠檬酸、苹果酸、酒石酸、苯甲酸、对甲基苯甲酸、对甲苯磺酸、甲基磺酸或萘磺酸)形成的酸加成盐。
可通过用1-6当量的碱(例如氢化钠、甲醇钠、乙醇钠、氢氧化钠、叔丁醇钾、氢氧化钙、醋酸钙、氯化钙、氢氧化镁、氯化镁等)处理式(I)化合物来制备形成本发明一部分的可药用盐。可使用的溶剂是例如水、丙酮、乙醚、THF、甲醇、乙醇、叔丁醇、二烷、异丙醇、异丙醚或其混合物。
实施例
使用适当的材料和适当的条件,根据以下实验程序制备本发明的新化合物。
制备1:2-溴-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-羧酸叔丁酯的制备
步骤(i):3-溴-4-氧代-哌啶-1-羧酸叔丁酯的制备
将4-氧代-哌啶-1-羧酸叔丁酯(10克,50mmol)和氯化铝(0.67克,5mmol)在四氢呋喃(30mL)和乙醚(30mL)中的溶液冷却至0℃,之后用溴(2.6mL,50mmol)处理30分钟。使反应物料在0-5℃搅拌24小时。反应完成后,过滤获得的固体,接着在真空下浓缩母液。用乙醚将获得的粗物质磨碎,过滤固体并在真空下干燥,从而获得标题化合物(10克)。
1H-NMR(δppm):1.51(9H,s),2.42-2.48(1H,m),3.04(1H,m),3.59-3.74(2H,m),3.97(2H,m),4.33(1H,m);
Mass(m/z):278(M+H)+,280(M+3H)+.
步骤(ii):2-氨基-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-羧酸叔丁酯的制备
将3-溴-4-氧代-哌啶-1羧酸叔丁酯(10克,35mmol,在上述步骤中获得的)和硫脲(3.28克,42mmol)在异丙醇(100mL)中的悬液回流1小时。反应完成后,浓缩反应物料并用乙醚(50mL)将所得粗物质磨碎,过滤固体并在真空下干燥,从而获得标题化合物(10克)。
1H-NMR(δppm):1.39(9H,s),2.52(2H,m),3.56-3.59(2H,t),4.30(2H,s),7.10(2H,bs);Mass(m/z):256(M+H)+.
步骤(iii):2-溴-6,7-氢-4H-噻唑并[5,4-c]吡啶-5-羧酸叔丁酯的制备
将2-氨基-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-羧酸叔丁酯(10克,40mmol,在上述步骤中获得的)和溴化铜(II)(9.6克,43mmol)在乙腈(50mL)中的溶液冷却至0℃。在0℃下经30分钟逐滴添加亚硝酸叔丁酯(5.1mL,43mmol)。使反应物料搅拌30分钟,然后用6N盐酸溶液淬灭反应物料。用乙酸乙酯(3×100mL)萃取产物,用水然后用盐水洗涤合并的有机层,接着经无水硫酸钠干燥。在真空下蒸发有机挥发物。通过快速色谱法(乙酸乙酯/正己烷,0.5/9.5)纯化获得的残余物,从而获得标题化合物(3.0克)。
1H-NMR(δppm):1.49(9H,s),2.85(2H,m),3.72(2H,m),4.56(2H,s);
Mass(m/z):319.3(M+H)+,321.3(M+H)+.
制备2:(2-溴-4,5,6,7-四氢-苯并噻唑-6-基)-氨基甲酸叔丁酯的制备
步骤(i):(3-溴-4-氧代-环己基)-氨基甲酸叔丁酯的制备
将(4-氧代-环己基)-氨基甲酸叔丁酯(10克,46mmol)和氯化铝(0.25克,2mmol)在四氢呋喃(30mL)和乙醚(30mL)中的溶液冷却至0℃,之后用溴(2.4mL,46mmol)处理30分钟。使反应物料在0-5℃搅拌24小时。反应完成后,过滤获得的固体,接着在真空下浓缩下面的滤液。用乙醚将获得的粗物质磨碎,过滤所得固体并在真空下干燥,从而获得标题化合物(9.0克)。
Mass(m/z):292.3(M+H)+,294.3(M+3H)+.
步骤(ii):2-氨基-4,5,6,7-四氢-苯并噻唑-6-基)-氨基甲酸叔丁酯的制备
将3-溴-4-氧代-哌啶-1-羧酸叔丁酯(9克,31mmol,在上述步骤中获得的)和硫脲(2.4克,31mmol)在异丙醇(100mL)中的悬液回流1小时。反应完成后,浓缩反应物料并用乙醚(50mL)将所得粗物质磨碎,过滤固体并在真空下干燥,从而获得标题化合物(9克)。
1H-NMR(δppm):1.38(9H,s),1.61-1.71(1H,m),1.84-1.86(1H,m),2.29-2.35(1H,m),2.53-2.57(2H,m),2.71-2.76(1H,m),3.71-3.76(1H,m),9.11(2H,s),12.86-12.93(1H,bs);
Mass(m/z):270.3(M+H)+.
步骤(iii):(2-溴-4,5,6,7-四氢-苯并噻唑-6-基)-氨基甲酸叔丁酯的制备
将2-氨基-4,5,6,7-四氢-苯并噻唑-6-基)-氨基甲酸叔丁酯(9克,33mmol,在上述步骤中获得的)和溴化酮(II)(8.3克,37mmol)在乙腈(70mL)中的溶液冷却至0℃。在0℃下将所得物料用亚硝酸叔丁酯(4.5mL,37mmol)处理30分钟。使反应物料搅拌30分钟,然后用6N盐酸溶液淬灭。用乙酸乙酯(3×100mL)萃取产物,用水然后用盐水洗涤合并的有机层,接着经无水硫酸钠干燥。在真空下蒸发有机挥发物。通过快速色谱法(乙酸乙酯/正己烷,0.5/9.5)纯化残余物,从而获得标题化合物(2.3克)。
1H-NMR(δppm):1.45(9H,s),1.89-1.93(1H,m),2.03-2.07(1H,m),2.59-2.63(1H,m),2.85-2.91(1H,m),3.09-3.13(1H,m),4.05-4.09(1H,m),4.63-4.66(1H,m),12.36-12.42(1H,bs);
Mass(m/z):333.1(M+H)+,335.3(M+3H)+.
实施例1:1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮酒石酸盐的制备
步骤(i):2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-羧酸叔丁酯的制备
用冷却的并搅拌的氢化钠(0.9克,18mmol)在四氢呋喃(20mL)中的悬液缓慢处理四氢呋喃(20mL)中的1-环丁基-哌啶-4-醇(1.6克,10mmol)30分钟;使反应混合物搅拌1小时。经15分钟逐滴添加2-溴-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-羧酸叔丁酯(3克,9mmol,在制备1中获得的)在四氢呋喃(30mL)中的溶液并使反应物回流6小时。用冰冷的水淬灭反应物料,然后用乙酸乙酯(3×50mL)萃取产物。用水 然后用盐水洗涤合并的有机层,接着经无水硫酸钠干燥。在真空下蒸发有机挥发物。通过快速色谱法(乙酸乙酯/正己烷,1/1)纯化残余物,从而获得标题化合物(2.0克)。
1H-NMR(δppm):1.48(9H,s),1.65-1.72(2H,m),1.85-1.92(4H,m),2.01-2.07(4H,m),2.18-2.19(2H,m),2.57(2H,m),2.62-2.66(2H,m),2.71-2.75(1H,m),3.70(2H,m),4.43(2H,m),4.93(1H,m);
Mass(m/z):394.2(M+H)+.
步骤(ii):2-(1-环丁基-哌啶-4-基氧基)-4,5,6,7-四氢-噻唑并[5,4-c]吡啶的制备
在0℃下用三氟乙酸(5.0mL,50mmol)处理2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-羧酸叔丁酯(2.0克,5mmol,在上述步骤中获得的)在二氯甲烷(30mL)中的溶液。使反应物料搅拌4小时。反应完成后,在冰冷的水中淬灭反应物料并通过使用40%氢氧化钠水溶液将pH调节至10。用二氯甲烷(3×50mL)萃取产物,用水然后用盐水洗涤合并的有机层,接着经无水硫酸钠干燥。在真空下蒸发有机挥发物,从而获得标题化合物(1.3克)。
1H-NMR(δppm):1.68-1.74(2H,m),1.85-1.93(4H,m),2.06(4H,m),2.19(2H,m),2.60-2.61(4H,m),2.73-2.80(1H,m),2.90-3.10(1H,m),3.13-3.16(2H,m),3.85(2H,s),4.90-4.93(1H,m);
Mass(m/z):294.2(M+H)+.
步骤(iii):1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮的制备
将2-(1-环丁基-哌啶-4-基氧基)-4,5,6,7-四氢-噻唑并[5,4-c]吡啶(1.3克,4mmol,在上述步骤中获得的)和三乙胺(1.9mL,13mmol)在二氯甲烷(30mL)中的溶液冷却至0℃。经15分钟逐滴添加二氯甲烷(5mL)中的丙酰氯(0.4mL,5mmol)并搅拌反应物30分钟。将反应物料倾倒至冰水上,然后用乙酸乙酯(3×50mL)萃取产物。用水然后用盐水洗涤合并的有机层,接着经无水硫酸钠干燥。在真空下蒸发有机挥发物。通过快速色谱法(甲醇/氯仿,2/98)纯化残余物,从而获得标题化合物(1.0克)。
1H-NMR(δppm):1.17-1.21(3H,m),1.65-1.72(5H,m),1.87-1.91(4H,m),2.01-2.07(4H,m),2.22(1H,m),2.38-2.45(2H,m),2.45(1H,m),2.68-2.76(3H,m),3.72-3.74(1H,m),4.47-4.62(2H,m),4.92-4.94(1H,m).
Mass(m/z):350.4(M+H)+.
步骤(iv):1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮酒石酸盐的制备
在0℃下用L(+)-酒石酸(0.34克,2.3mmol)处理1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮(0.8克,2.3mmol,在上述步骤中获得的)在甲醇(10mL)中的溶液。使反应物料搅拌约1小时,然后在真空下蒸发溶剂至干。用乙醚洗涤固体并在真空下干燥,从而获得标题化合物(1.1克)。
1H-NMR(δppm):1.12-1.20(3H,m),1.82-1.87(2H,m),2.16-2.32(7H,m),2.45-2.55(2H,m),2.63-2.66(3H,m),2.72(1H,m),3.20(2H,m),3.47-3.50(1H,m),3.66-3.70(1H,m),3.81-3.88(2H,m),4.45(2H,s),4.60(2H,s),5.18(5H,m);
Mass(m/z):350.4(M+H)+.
实施例2:[2-(4-环丁基-环己氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-环丙基-甲酮酒石酸盐的制备
步骤(i):1-环丙甲酰基-氮杂环庚-4-酮的制备
将氮杂环庚-4-酮(1.75克,15.3mmol)和三乙胺(6.45mL,3.1mmol)在二氯甲烷(15mL)中的溶液冷却至0℃。添加二氯甲烷(2mL)中的环丙酰氯(0.17mL,1.8mmol)并搅拌反应物30分钟。将反应物料倾倒至冰冷的水上,然后用二氯甲烷(3×15mL)萃取产物。用水然后用盐水洗涤合并的有机层,接着经无水硫酸钠干燥。在真空下蒸发有机挥发物,从而获得标题化合物(2.7克)。
1H-NMR(δppm):0.66-0.69(4H,m),1.56-1.57(1H,m),1.71-1.75(1H,m),1.87-1.89(1H,m),2.45-2.49(1H,m),2.59-2.62(1H,m),3.57-3.91(4H,m);
Mass(m/z):182(M+H)+.
步骤(ii):5-溴-1-环丙甲酰基-氮杂环庚-4-酮的制备
将1-环丙甲酰基-氮杂环庚-4-酮(2.7克,14.9mmol,在上述步骤中获得的)在醋酸(30mL)中的溶液冷却至10℃,然后用溴(0.71mL, 14.9mmol)处理15分钟。使所得浆液在氮气氛下搅拌18小时。反应完成后,将物料浓缩至干,从而获得标题化合物(3.87克)。
Mass(m/z):260,262(M+H)+.
步骤(iii):(2-氨基-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基)-环丙基-甲酮的制备
将5-溴-1-环丙甲酰基-氮杂环庚-4-酮(3.87克,14.8mmol,在上述步骤中获得的)和硫脲(1.13克,14.8mmol)在异丙醇(40mL)中的悬液回流6小时。反应完成后,浓缩反应物料,然后通过快速色谱法(甲醇/氯仿,3/97)纯化获得的残余物,从而获得标题化合物(0.4克)。
1H-NMR(δppm):0.66-0.73(4H,m),1.95(1H,m),2.66-2.69(2H,m),2.75-2.76(2H,m),3.55-3.62(2H,m),3.79-3.86(2H,m),6.61(2H,bs);
Mass(m/z):238(M+H)+.
步骤(vi):(2-溴-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基)-环丙基-甲酮的制备
将(2-氨基-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基)-环丙基-甲酮(0.4克,1.68mmol,在上述步骤中获得的)和溴化铜(II)(0.37克,1.68mmol)在乙腈(40mL)中的溶液冷却至0℃。在0℃下经10分钟逐滴添加亚硝酸叔丁酯(0.2mL,1.68mmol)。使反应物料搅拌30分钟,然后用3N盐酸溶液淬灭反应物料。用乙酸乙酯(3×15mL)萃取产物,用水然后用盐水洗涤合并的有机层,接着经硫酸钠干燥。在真空下蒸发有机挥发物。通过快速色谱法(乙酸乙酯/正己烷,7/3)纯化由此获得的残余物,从而获得标题化合物(0.053克)。
1H-NMR(δppm):0.71-0.75(4H,m),1.97(1H,m),2.86-2.92(2H,m),2.99-3.08(2H,m),3.61-3.86(2H,m),3.86-3.90(2H,m);
Mass(m/z):301(M+H)+.
步骤(v):[2-(4-环丁基哌啶-4基-氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-环丙基-甲酮的制备
用冷却的并搅拌的氢化钠(0.021克,0.51mmol)在四氢呋喃(8mL)中的悬液缓慢处理四氢呋喃(3mL)中的1-环丁基-哌啶-4-醇(0.04克,0.26mmol)5分钟,然后使反应混合物在室温下搅拌2小时。经5分钟逐滴添加(2-溴-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基)-环丙基-甲酮(0.053 克,0.17mmol,在上述步骤中获得的)在四氢呋喃(3mL)中的溶液并回流15小时。在冰冷的水上淬灭反应物料,然后用乙酸乙酯(3×10mL)萃取产物。用水然后用盐水洗涤合并的有机层,接着经无水硫酸钠干燥。在真空下蒸发有机挥发物。通过快速色谱法(甲醇/氯仿,3/97)纯化获得的残余物,从而获得标题化合物(0.05克)。
1H-NMR(δppm):0.84-0.86(4H,m),0.91(1H,m),1.73-1.76(2H,m),1.86-1.93(4H,m),2.07-2.08(5H,m),2.63(2H,m),2.80-2.84(2H,m),2.93-2.99(3H,m),3.74-3.79(2H,m),3.94-4.00(2H,m).
Mass(m/z):376.4(M+H)+.
步骤(vi):[2-(1-环丁基-哌啶-4-基氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂 -6-基]-环丙基-甲酮酒石酸盐的制备
在0℃下用L(+)-酒石酸(0.031克,0.208mmol)处理[2-(4-环丁基-环己氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-环丙基-甲酮(0.078克,0.208mmol,在上述步骤中获得的)在甲醇(5mL)中的溶液。使反应物料搅拌约1小时,然后在真空下蒸发溶剂至干。用乙醚洗涤固体并在真空下干燥,从而获得标题化合物(0.1克)。
1H-NMR(δppm):0.84-0.99(4H,m),1.83-1.90(2H,m),2.00-2.02(1H,m),2.18-2.23(5H,m),2.32-2.41(2H,m),2.82-2.87(2H,m),2.95-2.99(2H,m),3.13-3.20(5H,m),3.62-3.66(1H,m),3.74-3.79(2H,m),3.95-3.99(2H,m),4.43(2H,s),5.13(1H,s).
Mass(m/z):376.4(M+H)+.
实施例3:N-[2-(1-环丁基-哌啶-4-基氧基)-4,5,6,7-四氢-苯并噻唑-6-基]-丙酰胺的制备
步骤(i):2-溴-4,5,6,7-四氢-苯并噻唑-6-基胺的制备
在0℃下用三氟乙酸(1.1mL,15mmol)处理(2-溴-4,5,6,7-四氢-苯并噻唑-6-基)-氨基甲酸叔丁酯(0.50克,1.5mmol,在制备2中获得的)在二氯甲烷(30mL)中的溶液。使反应物料搅拌4小时。反应完成后,用冰冷的水淬灭物料,然后通过使用40%氢氧化钠水溶液将pH调节至10。用二氯甲烷(3×50mL)萃取产物,用水然后用盐水洗涤合并的有机层,接着经无水硫酸钠干燥。在真空下蒸发有机挥发物,从而获得标题化合物(0.36克)。
Mass(m/z):233.0(M+H)+,235.0(M+3H)+.
步骤(ii):N-(2-溴-4,5,6,7-四氢-苯并噻唑-6-基)-丙酰胺的制备
将2-溴-4,5,6,7-四氢-苯并噻唑-6-基胺(0.36克,1.5mmol,在上述步骤中获得的)和三乙胺(0.43mL,mmol)在二氯甲烷(15mL)中的溶液冷却至0℃。添加二氯甲烷(2mL)中的丙酰氯(0.17mL,1.8mmol),然后使反应物料搅拌30分钟。反应完成后,将物料倾倒至冰冷的水上,然后用乙酸乙酯(3×15mL)萃取产物。用水然后用盐水洗涤合并的有机层,经无水硫酸钠干燥,接着在真空下蒸发有机挥发物。通过快速色谱法(甲醇/氯仿,2/98)纯化残余物,从而获得标题化合物(0.4克)。
1H-NMR(δppm):0.81-0.85(1H,m),1.14-1.18(3H,m),1.20-1.28(2H,m),1.90-1.96(1H,m),2.02-2.05(1H,m),2.18-2.23(2H,m),2.57-2.63(1H,m),2.86-2.91(1H,m),3.10-3.15(1H,m);
Mass(m/z):289.2(M+H)+,291.2(M+3H)+.
步骤(iii):N-[2-(1-环丁基-哌啶-4-基氧基)-4,5,6,7-四氢-苯并噻唑-6-基]-丙酰胺的制备
用冷却的并搅拌的氢化钠(0.1克,2.08mmol)在N,N-二甲基甲酰胺(10mL)中的悬液缓慢处理N,N-二甲基甲酰胺(5mL)中的1-环丁基-哌啶-4-醇(0.25克,1.6mmol)30分钟,然后使反应混合物再搅拌1小时。经10分钟逐滴添加N-2-溴-4,5,6,7-四氢-苯并噻唑-6-基)-丙酰胺(0.4克,1.3mmol,在上述步骤中获得的)在N,N-二甲基甲酰胺(5mL)中的溶液并使所得物料搅拌48小时。反应完成后,在冰冷的水上淬灭物料,然后用乙酸乙酯(3×15mL)萃取产物。用水然后用盐水洗涤合并的有机层,经无水硫酸钠干燥,接着在真空下蒸发有机挥发物。通过快速色谱法(乙酸乙酯/正己烷,1/1)纯化残余物,从而获得标题化合物(0.068克)。
1H-NMR(δppm):0.81-0.88(2H,m),1.14-1.18(3H,m),1.65-1.70(2H,m),1.89-1.91(5H,m),2.03-2.05(5H,m),2.17-2.23(3H,m),2.49-2.75(4H,m),2.96-3.01(2H,m),4.35-4.39(1H,m),4.90-3.96(1H,m),5.50-5.53(1H,m);
Mass(m/z):364.3(M+H)+.
实施例4-34:
通过根据实施例1至3描述的程序(具有一些非关键性变化)制备实施例4-34的化合物。
实施例35-66:
本领域技术人员可根据上述程序制备实施例35-66的化合物。
生物测定
实施例67:人或大鼠组胺H3受体的结合和功能测定
可根据以下程序评估化合物。
材料和方法:
受体来源:大鼠脑额皮质或CHO细胞中表达的重组人cDNA
放射性配体:[3H]R-α-甲基组胺
最终配体浓度-[3.0nM]
非特异性决定因子:R-α-甲基组胺(100μM)
参照化合物:R-α-甲基组胺
阳性对照:R-α-甲基组胺
孵育条件:
在室温下将测试化合物或标准品与5mM MgCl2和50mM TRIS-HCl(pH7.4)中的膜受体和放射性配体一起孵育60分钟。通过快速真空过滤至玻璃纤维过滤器上来终止反应。确定在过滤器上捕获的放射性并且与对照值相比较,从而确定测试化合物与克隆的人或大鼠受体结合位点的任何相互作用。
实施例编号 | Ki(nM) |
1. | 3.83 |
2. | 2.0 |
3. | 26.67 |
4. | 7.2 |
5. | 3.3 |
6. | 13.4 |
7. | 10.5 |
8. | 7.69 |
9. | 9.94 |
10. | 5.43 |
11. | 11.98 |
12. | 8.44 |
14. | 23.6 |
16. | 33.55 |
17. | 21.2 |
18. | 6.96 |
19. | 12.28 |
20. | 7.4 |
21. | 22.6 |
22. | 9.5 |
23. | 0.3 |
25. | 35.33 |
26. | 32.54 |
27. | 0.75 |
28. | 38.96 |
29. | 11.3 |
30. | 4.19 |
31. | 1.62 |
32. | 4.6 |
33. | 15.45 |
34. | 15.6 |
文献参考:Millipore数据表
实施例68:啮齿动物药代动力学研究
将从NIN(国家营养学会(National Institute of Nutrition),Hyderabad, India)获得的雄性Wistar大鼠(230-280g)用作实验动物。在每只笼子中装有3只动物。使动物保持禁食过夜并且以12小时的明暗周期(light/dark cycle)维持。在第0天和第2天用新化学实体(New chemical entity,NCE)对三只大鼠口服(3或10mg/kg)和静脉内(1或5mg/kg)给药。
在每个时间点,通过颈静脉采集血液。将血液贮存在2-8℃直到分析。使用LC-MS/MS法确定NCE化合物在血液中的浓度。预定时间点:给药前,给药后0.08、0.25、0.5、1、2、4、6、8和24小时(n=3)。使用乙腈沉淀技术通过部分验证的LC-MS/MS法(partially validated LC-MS/MS method)在血液中定量NCE化合物。在血液中,在1-2000ng/mL的校准范围中定量NCE化合物。使用批次内校准样品和批次间品质对照样品来分析研究样品。
使用软件WinNonlin 5.0.1版通过非区室模型(non-compartmental model)计算药代动力学参数。
实施例69:啮齿动物脑渗透研究
将从NIN(国家营养学会,Hyderabad,India)获得的雄性Wistar大鼠(230-280克)用作实验动物。在每只笼子中装有3只动物。整个实验随意给动物水和食物,并且以12小时的明暗周期维持。
将新化学实体(NCE)溶解在合适的载剂中并口服施用(3或10mg/kg)。在约Tmax(即,0.5小时、1.0小时和2.0小时)时处死动物。采集血液和脑组织并将脑匀浆化至产生20%w/v。将血液贮存在2-8℃和将脑匀浆在-20℃冷冻直到分析。使用LC-MS/MS法定量NCE在血液和脑中的浓度。
使用乙腈沉淀技术通过部分验证的LC-MS/MS法在血液和脑匀浆中定量NCE。在血液和脑匀浆中,在1-500ng/mL的校准范围中定量NCE化合物。使用批次内校准样品和批次间品质对照样品来分析研究样品。计算脑-血液比率的范围(Cb/Cp)。
实施例70:物体识别任务模型
通过使用该模型评估本发明化合物的认知增强特性。
将从N.I.N.(国家营养学会,Hyderabad,India)获得的雄性Wistar大鼠(230-280克)用作实验动物。在每只笼子中装有4只动物。在一天前使动物保持20%食物剥夺以及整个实验随意给动物水,并且以12小时的明暗周期维持。另外,在不存在任何物体的情况下使大鼠动物习惯各个场地(arena)1小时。
在熟悉(T1)和选择试验(T2)前1小时,使一组12只大鼠口服接受载剂(1mL/Kg)以及另一组动物口服或腹腔(i.p.)接受式(I)化合物。
在由丙烯酸制成的50×50×50cm旷场(open field)中进行实验。在熟悉阶段(T1),将大鼠各自放入旷场中3分钟,其中用黄色遮蔽胶带单独覆盖的两个相同的物体(塑料瓶,12.5cm高×5.5cm直径)(a1和a2)放置在两个毗连的角落,离墙有10cm。在长期记忆测试的(T1)试验的24小时后,将同一批大鼠放入如它们在T1试验被放入的同一场地中。选择阶段(T2),使得大鼠在熟悉的物体(a3)和一个新的物体(b)(琥珀色玻璃瓶,12cm高和5cm直径)的存在下探索旷场3分钟。熟悉的物体表现出类似的质地、颜色和尺寸。在T1和T2试验期间,通过秒表分开记录对每个物体的探索(其定义为嗅、舔、嚼或移动触须同时在少于1cm的距离使鼻子朝向物体)。坐在物体上不被认为是探索行为,然而极少被观察到。
T1是探索熟悉的物体(a1+a2)花费的总时间。
T2是探索熟悉的物体和新的物体(a3+b)花费的总时间。
通过Ennaceur,A.,Delacour,J.,1988,A new one-trial test for neurobiological studies of memory in rats-Behavioural data,Behav. Brain Res.,31,47-59所描述的那样进行物体识别测试。
实施例71:莫里斯(Morris)水迷宫
通过使用该模型评估本发明化合物的认知增强特性。
用水(24±2℃)充满由在黑色有机玻璃(Perspex)中构建的循环池(1.8m直径,0.6m高)组成的水迷宫装置(TSE systems,Germany)并将该装置放置在广角摄像机的下方以追踪动物。将位于水表面下1cm的10cm2有机玻璃平台放入四个虚构象限(imaginary quadrant)之一的中心,其对于所有的大鼠保持固定。用于构建迷宫和平台的黑色有机玻璃不提供指导脱逃行为的迷宫内线索。相比之下,训练室提供了数个强烈的迷宫外视觉线索以帮助形成脱逃学习必需的空间地图。使用自动追踪系统[Videomot2(5.51),TSE systems,Germany]。该程序经由数字摄像机和图像采集板分析取得的视频图像,从而确定在水迷宫的每个象限中路径长度、游泳速度和进入次数以及花费的游泳持续时间。
实施例编号 | 东莨菪碱诱导的健忘症的逆转 |
1. | ≤10mg/kg,经口 |
4. | ≤10mmg/kg,经口 |
5. | ≤3mmg/kg,经口 |
12. | ≥20mg/kg,经口 |
28. | ≥10mg/kg,经口 |
实施例72:食物摄取的抑制
通过使用该模型评估本发明化合物的抗肥胖症特性。
实验由6天组成。使大鼠适应18小时禁食和6小时饲喂模式。在配置有禁食栅格(fasting grill)的笼子中以3只一组装入动物并使动物禁食18小时。在18小时禁食后,将大鼠分开并单独放入笼子中。将经称重量 的食物提供给大鼠6小时,并且在1小时、2小时、4小时和6小时测量食物摄取。
将大鼠再重新分组并禁食18小时。根据上述程序进行5天。计算最后3天大鼠的平均积累食物摄取。在动物之前3天的食物摄取的基础上将它们随机化。在实验当天,用测试化合物或载剂口服处理大鼠。60分钟后,给大鼠提供食物并在1小时、2小时、4小时和6小时测量食物摄取。通过使用非配对的t检验(Unpaired Student’s t test),将用测试化合物处理的大鼠的食物摄取与载剂处理组相比较。
实施例编号 | 食物摄取的抑制 |
4. | 20mmg/kg,p.o. |
Claims (12)
1.通式(I)的化合物或其可药用盐:
其中,
R1是
R2是异丙基、异丁基、环丙基或环丁基;
R3是氢;
X是S;
Y是N;
“p”是整数1;
“q”是1至2的整数;
“r”是整数1。
2.根据权利要求1所述的化合物,其选自:
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-丙-1-酮酒石酸盐;
[2-(4-环丁基-环己氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-环丙基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-环丙基-甲酮酒石酸盐;
环丁基-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-(2-氟-苯基)-甲酮酒石酸盐;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-3-甲基-丁-1-酮酒石酸盐;
环丁基-[2-(1-异丙基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮;
环丙基-[2-(1-异丙基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
环丙基-[2-(1-环丙基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
环丁基-[2-(1-环丙基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-2-吗啉-4-基-乙酮酒石酸盐;
[4-(5-环丁基-4,5,6,7-四氢-4H-噻唑并[5,4-c]吡啶-2-基氧基)-哌啶-1-基]-环丙基-甲酮酒石酸盐;
[3-(5-环丁基-4,5,6,7-四氢-4H-噻唑并[5,4-c]吡啶-2-基氧基)-哌啶-1-基]-环丙基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-3-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-环丙基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-吡啶-4-基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-(4-甲氧基-苯基)-甲酮酒石酸盐;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-2-哌啶-1-基-乙酮酒石酸盐;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-2-环丙基-乙酮;
2-(1-环丁基-哌啶-4-基氧基)-5-(2-氟-苯磺酰基)-4,5,6,7-四氢-噻唑并[5,4-c]吡啶酒石酸盐;
2-(1-环丁基-哌啶-4-基氧基)-5-甲磺酰基-4,5,6,7-四氢-噻唑并[5,4-c]吡啶;
1-[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-2-甲基-丙-1-酮酒石酸盐;
2-(1-环丁基-哌啶-4-基氧基)-5-(6-三氟甲基-吡啶-3-基)-4,5,6,7-四氢-噻唑并[5,4-c]吡啶;
环丙基-[2-(1-异丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-(6-三氟甲基-吡啶-3-基)-甲酮;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-吡啶-3-基-甲酮酒石酸盐;
2-(1-环丁基-哌啶-4-基氧基)-5-吡啶-3-基-4,5,6,7-四氢-噻唑并[5,4-c]吡啶酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-(四氢-吡喃-4-基)-甲酮;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-吗啉-4-基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-哌啶-1-基-甲酮盐酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-4H-噻唑并[5,4-c]吡啶-5-基]-环戊基-甲酮酒石酸盐;
[2-(1-环丁基-哌啶-4-基氧基)-6,7-二氢-5H-噻唑并[5,4-b]吡啶-4-基]-环丙基-甲酮酒石酸盐;和
环丙基-[2-(1-异丙基-哌啶-4-基氧基)-4,5,7,8-四氢-噻唑并[5,4-d]氮杂-6-基]-甲酮酒石酸盐。
3.一种药物组合物,其包含权利要求1或2所述的化合物和可药用赋形剂。
4.根据权利要求3所述的药物组合物,其用于治疗临床病症。
5.根据权利要求4所述的药物组合物,其中所述临床病症选自认知障碍、睡眠障碍、肥胖症和疼痛。
6.用于制备根据权利要求1所述的式(I)化合物的方法,其包括(a)将式(1)化合物与式(2)化合物相偶联
以形成式(3)化合物,
(b)使式(3)化合物脱保护以形成式(4)化合物,
(c)将式(4)化合物与式(5)化合物相偶联
R1-Cl
(5)
以形成式(I)化合物,其中所有的取代基如权利要求1中所定义,
(d)任选地将式(I)化合物转化成其可药用盐。
7.用于制备根据权利要求1所述的式(I)化合物的方法,其包括:
(a)将式(6)化合物与式(5)化合物相偶联
以形成式(7)化合物,
(b)使式(7)化合物溴化以形成式(8)化合物,
(c)使式(8)化合物环化以形成式(9)化合物,
(d)使式(9)化合物重氮化以形成式(10)化合物,
(e)将式(10)化合物与式(2)化合物相偶联
以形成式(I)化合物,其中所有的取代基如权利要求1中所定义,
(f)任选地,将式(I)化合物转化成其可药用盐。
8.用于制备根据权利要求1所述的式(I)化合物的方法,其包括:
(a)将式(11)化合物与式(5)化合物相偶联,
以形成式(12)化合物,
(b)将式(12)化合物与式(2)化合物相偶联
以形成式(I)化合物,其中所有的取代基如权利要求1中所定义,
(c)任选地,将式(I)化合物转化成其可药用盐。
9.根据权利要求1的化合物,其用于制备治疗与组胺H3受体有关的疾病的药物。
10.根据权利要求1或2的化合物在制备用于治疗组胺H3受体相关疾病的药物中的用途。
11.根据权利要求10所述的化合物的用途,其用于治疗临床病症。
12.根据权利要求11所述的化合物的用途,其中所述临床病症选自认知障碍、睡眠障碍、肥胖症和疼痛。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2551CH2010 | 2010-09-02 | ||
IN2551/CHE/2010 | 2010-09-02 | ||
PCT/IN2010/000740 WO2012029070A1 (en) | 2010-09-02 | 2010-11-15 | Heterocyclyl compounds as histamine h3 receptor ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103079566A CN103079566A (zh) | 2013-05-01 |
CN103079566B true CN103079566B (zh) | 2015-06-17 |
Family
ID=43608695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080068911.8A Expired - Fee Related CN103079566B (zh) | 2010-09-02 | 2010-11-15 | 作为组胺h3受体配体的杂环基化合物 |
Country Status (27)
Country | Link |
---|---|
US (1) | US8912179B2 (zh) |
EP (1) | EP2611444B1 (zh) |
JP (1) | JP5650329B2 (zh) |
KR (1) | KR101538239B1 (zh) |
CN (1) | CN103079566B (zh) |
AU (1) | AU2010360038B2 (zh) |
BR (1) | BR112013005084A2 (zh) |
CA (1) | CA2812970C (zh) |
CY (1) | CY1117096T1 (zh) |
DK (1) | DK2611444T3 (zh) |
EA (1) | EA022746B1 (zh) |
ES (1) | ES2558531T3 (zh) |
HK (1) | HK1180955A1 (zh) |
HR (1) | HRP20151380T1 (zh) |
HU (1) | HUE028435T2 (zh) |
IL (1) | IL224652A (zh) |
ME (1) | ME02320B (zh) |
MX (1) | MX354852B (zh) |
NZ (1) | NZ607658A (zh) |
PL (1) | PL2611444T3 (zh) |
PT (1) | PT2611444E (zh) |
RS (1) | RS54514B1 (zh) |
SG (1) | SG188212A1 (zh) |
SI (1) | SI2611444T1 (zh) |
SM (1) | SMT201600012B (zh) |
WO (1) | WO2012029070A1 (zh) |
ZA (1) | ZA201301143B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME02519B (me) * | 2012-08-23 | 2017-02-20 | Suven Life Sciences Ltd | Jedinjenja akrilamida kao ligandi histaminskog h3 receptora |
CN104530088A (zh) * | 2014-12-08 | 2015-04-22 | 苏州施亚生物科技有限公司 | 2-氨基-6,7-二氢-5H-噻唑并[5,4-b]吡啶-4-羧酸叔丁酯及其衍生物,以及它们的合成方法 |
EP3378477A1 (en) * | 2017-03-21 | 2018-09-26 | BIOPROJET Pharma | New therapeutical use of h3-ligands |
JP2021501764A (ja) | 2017-11-02 | 2021-01-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | B型肝炎ウイルス(hbv)に対して有効な新規高活性アミノチアゾール置換インドール−2−カルボキサミド |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101547926A (zh) * | 2006-12-08 | 2009-09-30 | 霍夫曼-拉罗奇有限公司 | 作为h3调节剂的4,5,6,7-四氢-噻吩并[3,2-c]吡啶衍生物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695575A (en) | 1984-11-13 | 1987-09-22 | Janssen Pharmaceutica, N.V. | 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines |
PH23995A (en) | 1984-01-09 | 1990-02-09 | Janssen Pharmaceutica Nv | 4((bicycle heterocyclyl)-methyl and hetero)piperidines |
AU2002344951A1 (en) | 2001-07-02 | 2003-01-21 | Boehringer Ingelheim International Gmbh | Substituted piperazine and diazepanes as histamine h3 receptor agonists |
CA2497827A1 (en) | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
EP1786775A1 (en) * | 2004-07-16 | 2007-05-23 | Janssen Pharmaceutica N.V. | Dimeric piperidine derivates |
MX2007000616A (es) * | 2004-07-16 | 2007-03-07 | Janssen Pharmaceutica Nv | Derivados dimericos de piperidina. |
ATE420091T1 (de) * | 2005-03-14 | 2009-01-15 | Glaxo Group Ltd | Kondensierte thiazolderivate mit affinität für den histamin-h3-rezeptor |
NZ570524A (en) * | 2006-03-28 | 2011-08-26 | High Point Pharmaceuticals Llc | Benzothiazoles having histamine H3 receptor activity |
WO2008012010A1 (en) * | 2006-07-27 | 2008-01-31 | Ucb Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
US20080146559A1 (en) * | 2006-12-08 | 2008-06-19 | Li Chen | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives |
NZ586399A (en) * | 2008-01-24 | 2011-12-22 | Ucb Pharma Sa | Compounds comprising a cyclobutoxy group |
WO2010026113A1 (en) | 2008-09-03 | 2010-03-11 | Evotec Neurosciences Gmbh | Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
-
2010
- 2010-11-15 RS RS20150868A patent/RS54514B1/en unknown
- 2010-11-15 JP JP2013526597A patent/JP5650329B2/ja not_active Expired - Fee Related
- 2010-11-15 SG SG2013010921A patent/SG188212A1/en unknown
- 2010-11-15 MX MX2013001988A patent/MX354852B/es active IP Right Grant
- 2010-11-15 US US13/818,152 patent/US8912179B2/en not_active Expired - Fee Related
- 2010-11-15 HU HUE10803396A patent/HUE028435T2/en unknown
- 2010-11-15 CA CA2812970A patent/CA2812970C/en not_active Expired - Fee Related
- 2010-11-15 AU AU2010360038A patent/AU2010360038B2/en not_active Ceased
- 2010-11-15 BR BR112013005084-5A patent/BR112013005084A2/pt not_active Application Discontinuation
- 2010-11-15 ES ES10803396.0T patent/ES2558531T3/es active Active
- 2010-11-15 SI SI201031083T patent/SI2611444T1/sl unknown
- 2010-11-15 CN CN201080068911.8A patent/CN103079566B/zh not_active Expired - Fee Related
- 2010-11-15 KR KR1020137005890A patent/KR101538239B1/ko active IP Right Grant
- 2010-11-15 PL PL10803396T patent/PL2611444T3/pl unknown
- 2010-11-15 PT PT108033960T patent/PT2611444E/pt unknown
- 2010-11-15 EA EA201390327A patent/EA022746B1/ru not_active IP Right Cessation
- 2010-11-15 EP EP10803396.0A patent/EP2611444B1/en active Active
- 2010-11-15 WO PCT/IN2010/000740 patent/WO2012029070A1/en active Application Filing
- 2010-11-15 DK DK10803396.0T patent/DK2611444T3/en active
- 2010-11-15 ME MEP-2015-216A patent/ME02320B/me unknown
-
2012
- 2012-12-24 NZ NZ607658A patent/NZ607658A/en not_active IP Right Cessation
-
2013
- 2013-02-10 IL IL224652A patent/IL224652A/en not_active IP Right Cessation
- 2013-02-11 ZA ZA2013/01143A patent/ZA201301143B/en unknown
- 2013-07-15 HK HK13108284.3A patent/HK1180955A1/zh not_active IP Right Cessation
-
2015
- 2015-12-15 HR HRP20151380TT patent/HRP20151380T1/hr unknown
- 2015-12-30 CY CY20151101205T patent/CY1117096T1/el unknown
-
2016
- 2016-01-14 SM SM201600012T patent/SMT201600012B/it unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101547926A (zh) * | 2006-12-08 | 2009-09-30 | 霍夫曼-拉罗奇有限公司 | 作为h3调节剂的4,5,6,7-四氢-噻吩并[3,2-c]吡啶衍生物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0675886A1 (en) | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists | |
EP2089397B1 (en) | 5- [4- (azetidin-3-yl0xy) -phenyl]-2-phenyl-5h-thiaz0l0 [5,4-c]pyridin-4-0ne derivatives and their use as mch receptor antagonists | |
TW202202497A (zh) | Gpr6的四氫吡啶並吡𠯤調節劑 | |
AU2012267622B2 (en) | Metabotropic glutamate receptor 5 modulators and methods of use thereof | |
WO2001058900A1 (fr) | Derives de 1h-imidazopyridine | |
WO2014054635A1 (ja) | イミダゾール誘導体 | |
CN103079566B (zh) | 作为组胺h3受体配体的杂环基化合物 | |
AU2009237050A1 (en) | 3-phenylpyrazolo[5,1-b]thiazole compound | |
CN110818704B (zh) | 螺桥环化合物、其药物组合物及其用途 | |
JP4530597B2 (ja) | アザインドリジノン誘導体及びそれを有効成分とする脳機能改善剤 | |
CN107074816B (zh) | 一种杂环衍生物及其制备方法和在医药上的用途 | |
CA2196078A1 (en) | Imidazopyridine-azolidinones | |
KR20120049943A (ko) | α₄β₂ 니코틴성 아세틸콜린 수용체 리간드로서 비시클릭 화합물 | |
JP2013166727A (ja) | ジヒドロイミダゾピラジノン誘導体 | |
CN115380036A (zh) | Sstr5拮抗剂 | |
US20120123127A1 (en) | Process for producing thiabenzoazulene-propionic acid derivative | |
WO2017213210A1 (ja) | 複素環化合物 | |
CA3180132A1 (en) | Pyrimidin-4(3h)-one derivatives as trpv4 antagonists | |
CN116848117A (zh) | 作为Wee-1抑制剂的稠环化合物 | |
CN117222648A (zh) | 作为Wee-1抑制剂的稠环化合物及其制备方法和用途 | |
CN117295743A (zh) | 作为Wee-1抑制剂的吡咯并嘧啶衍生物 | |
KR20190132703A (ko) | 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1180955 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1180955 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150617 Termination date: 20201115 |
|
CF01 | Termination of patent right due to non-payment of annual fee |